Navigation Links
ARIUS sale approved by shareholders
Date:9/18/2008

TORONTO, Sept. 18 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that ARIUS Research Inc. shareholders and warrant holders approved the proposed plan of arrangement involving the Company and Roche.

At a special meeting held in Toronto on September 16, 2008, ARIUS shareholders and warrant holders approved the transaction, with 99.99% of Common Shareholders and Class F Warrant holders, voting as a class, and 100% of Class G Warrant holders, represented in person or by proxy, voting in favor of the transaction. The completion of the transaction will result in Common Shareholders receiving $2.44 per Common Share, holders of Class F Warrants receiving $1.44 per Class F Warrant, and holders of Class G Warrants receiving $1.78 per Class G Warrant. The transaction is subject to final Court approval on September 19, 2008, and is expected to close shortly after obtaining Court approval and upon the satisfaction of certain closing conditions.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
2. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
3. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
4. ARIUS to present at Chinese Global Financial Forum
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
8. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
9. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... ended June 30, 2014.  Biorem,s complete 2014 second quarter financial statements and ... Summary:Three-months ended June 30, , Six-months ended June ... , 2013 , 2014 , 2013 ... , 9,195 Gross profit , 56 , ...
(Date:8/22/2014)... published today (August 22nd), in the scientific journal ... Neuroscience Programme establish the effect of serotonin on ... genetic and optical techniques., "Serotonin is a small ... range of brain functions, from the control of ... emotional behaviours, This neurotransmitter is also popularly thought ...
(Date:8/22/2014)... investigated for application as catalysts, sensors, drug ... in photonics and molecular electronics. Gaining knowledge ... physical and chemical properties, has been challenging. ... demonstrated that high-resolution electron microscopy can be ... which all gold atoms are observed. The ...
(Date:8/22/2014)... The Global and China Diabetes Drugs Industry ... state of the Diabetes Drug industry in Global and ... the industry, including definitions, applications and industry chain structure. ... provided with a focus on history, developments, trends and ... international and Chinese situation is also offered. , The ...
Breaking Biology Technology:Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3From happiness to pain: Understanding serotonin's function 2A breakthrough in imaging gold nanoparticles to atomic resolution by electron microscopy 2Diabetes Drugs Industry Growth Analysis in Global, China Regions Research Report Available at DeepResearchReports.com 2Diabetes Drugs Industry Growth Analysis in Global, China Regions Research Report Available at DeepResearchReports.com 3
... , MISSOULA, Mont., June 24 VEGA PROMOTIONAL SYSTEMS, ... owned subsidiary, Natural Fuels Industries, it is planning to ... to produce alternative energy from organic waste. , ... "America,s Best Places For Alternative Energy," the abundance of ...
... BOTHELL, WA, and VANCOUVER, June 24 /PRNewswire-FirstCall/ - OncoGenex ... that the company has reached an agreement with the ... protocol assessment process (SPA) on an amendment to the ... its lead product candidate targeting castrate resistant prostate cancer ...
... Higher Percentage of Patients Have Preventative Testing , ... Advice Networks , the nation,s leading provider of ... Healthy Advice educational programs, 16.9 percent more ... percent more patients had colonoscopies (colon cancer screening) compared ...
Cached Biology Technology:Natural Fuels Industries Eyes 'Biomass Rich' Georgia for Production Facility 2Natural Fuels Industries Eyes 'Biomass Rich' Georgia for Production Facility 3OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 2OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 3OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 4OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 5Healthy Advice Networks Announces Improved Patient Outcomes in Physicians' Offices with Healthy Advice Programs 2
(Date:8/21/2014)... previously unknown process for harvesting energy and producing oxygen ... State University scientist has discovered. The discovery lays the ... harvesting energy from the Sun, and understanding dense blooms ... lakes worldwide. A paper describing the discovery will be ... the journal Science on 21 August 2014. ...
(Date:8/21/2014)... Israel Deaconess Medical Center (BIDMC ) are among the ... Minds 2014," a comprehensive list compiled by ... science metrics and research performance analysis. , ... performing and publishing work that their peers recognized as ... a Thomson Reuters statement. Researchers were identified based on ...
(Date:8/21/2014)... study recently published in the journal Carcinogenesis ... new role for the protein adenomatous polyposis coli (APC) ... cancer-related deaths in the U.S. , Lead author Kristi ... and co-leader of the Cancer Biology program at the ... her career trying to understand the various activities of ...
Breaking Biology News(10 mins):Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3
... The citrus disease Huanglongbing (HLB), meaning "yellow shoot ... in English-speaking countries, is the most destructive disease ... tools and management strategies are desired to control ... phosphorus deficiency as a contributing factor in symptom ...
... species of scorpion, Vaejovis brysoni, was found in the ... the same group also inhabits this mountain range, making this ... species distributed on the same mountain. The study was published ... . These mountains overlook the city of Tucson, Arizona. ...
... Sloan Foundation is pleased to announce the selection of ... Sloan Research Fellowships for 2013. , Awarded annually ... and scholars whose achievements and potential identify them as ... "The Sloan Research Fellows are the best of the ...
Cached Biology News:Phosphorus starvation linked to symptoms of citrus disease Huanglongbing in new study 2Phosphorus starvation linked to symptoms of citrus disease Huanglongbing in new study 3Sloan Foundation announces 2013 Sloan Research Fellows 2
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....
MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...
Biology Products: